All
All

What are you looking for?

All
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”
NR8145

Biology of chemosensitization of ovary and breast tumour cells tested for chemosensitivity/resistance in vitro and consequences for therapeutic indication.

Project goals

Untargeted chemotherapy of tumours is usually unsuccessful in 30% in the first line. Tests of chemoresistance in vitro should exclude cytostatics to which the cells are resistant. The MTT test will respond to the question only in the yes/no manner. The non-invasive test of specific response (NTSR) should give a more detailed response on the course and mechanism of resistance. In NTSR it is possible to influence cells by chemosensitors, combine cytostatics and follow the long-term cell response. A new mammary cell line L154 will be characterized and using the MTT and NTSR tests, pretreatment with tamoxifen before application of cytostatics will be tested on this line. The results will be used for determination of chemoresistance of patients.

Keywords

chemoresistancechemosensitizerMTT testovarial tumourmammary tumoursoestrogen receptoranti-oestrogensNTSR test

Public support

  • Provider

    Ministry of Health

  • Programme

    Branch programm of research of the Ministry of Health

  • Call for proposals

    VaV pro Ministerstvo zdravotnictví 1 (SMZ02004NR)

  • Main participants

  • Contest type

    VS - Public tender

  • Contract ID

Alternative language

  • Project name in Czech

    Biologie interakce chemosenzitorů s buňkami ovariálních a prsních nádorů testovaných na chemorezistenci in vitro a důsledky pro terapeutickou indikaci.

  • Annotation in Czech

    Necílená chemoterapie nádorů bývá v první linii ve 30% neúspěšná. Testy chemosenzitivity/rezistence in vitro by měly ve 2. linii terapie vyloučit cytostatika, na která jsou buňky nádoru rezistentní. MTT test na otázku rezistence odpoví pouze ano/ne. Neinvazivní test specifické odpovědi (NTSO) by měl dát detailnější odpověď o průběhu a mechanizmu rezistence. V NTSO je možno předem ovlivnit buňky chemosenzitory, kombinovat cytostatika a dlouhodobě sledovat buněčnou odpověď. Bude charakterizována nová mamární linie L154 a na ní pomocí MTT a NTSO testováno předléčení tamoxifenem (chemosenzitor)před aplikací cytostatik. Výsledky budou použity pro stanovení chemorezistence nádorů jednotlivých pacientů.

Scientific branches

  • R&D category

    NV - Nonindustrial research (Applied research excluded Industrial research)

  • CEP classification - main branch

    FD - Oncology and haematology

  • CEP - secondary branch

    FR - Pharmacology and apothecary chemistry

  • CEP - another secondary branch

  • 30104 - Pharmacology and pharmacy
    30204 - Oncology
    30205 - Hematology

Completed project evaluation

  • Provider evaluation

    V - Vynikající výsledky projektu (s mezinárodním významem atd.)

  • Project results evaluation

    A new cell line EM-G3 derived from breast cancer progenitors was established and characterized. A chemosensitivity test named Non-destructive test of cellular activity was developed. The effect of cytostatics was studied by NTCA and microcinematography.

Solution timeline

  • Realization period - beginning

    Jan 1, 2004

  • Realization period - end

    Jan 1, 2006

  • Project status

    U - Finished project

  • Latest support payment

Data delivery to CEP

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

  • Data delivery code

    CEP07-MZ0-NR-U/06:2

  • Data delivery date

    Aug 8, 2007

Finance

  • Total approved costs

    2,045 thou. CZK

  • Public financial support

    1,565 thou. CZK

  • Other public sources

    456 thou. CZK

  • Non public and foreign sources

    0 thou. CZK

Basic information

Recognised costs

2 045 CZK thou.

Public support

1 565 CZK thou.

76%


Provider

Ministry of Health

CEP

FD - Oncology and haematology

Solution period

01. 01. 2004 - 01. 01. 2006